Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma

Abstract excerpt

Therapy of BRAF -mutant melanoma with selective inhibitors of BRAF (BRAFi) and MEK (MEKi) represents a major clinical advance but acquired resistance to therapy has emerged as a key obstacle. To date, no clinical approaches successfully resensitize to BRAF/MEK inhibition. Here, we develop a therapeutic strategy for melanoma using bromosporine, a bromodomain inhibitor. Bromosporine (bromo) monotherapy produced...

Topics

Join the communities discussing this publication.

• CAR-T cell therapy research
• Multiple Myeloma Research and Treatments
• Protein Degradation and Inhibitors